Reviva Pharmaceuticals Holdings, Inc. announced that the first patients have been dosed in a pivotal Phase III study and long-term safety trial to assess Reviva’s new chemical entity brilaroxazine for the treatment of subjects with an acute exacerbation of schizophrenia.
[Reviva Pharmaceuticals Holdings, Inc.]
Sorry, but the selected Zotpress account can't be found.
